Amylyx (AMLX) stock ripped higher on Tuesday after the pharmaceutical firm reported promising Phase 3 clinical trial data for its candidate drug, avexitide.
In its press release, AMLX said its avexitide, a first-in-class GLP-1 receptor antagonist for post-bariatric hypoglycemia, demonstrated a 55% reduction in hypoglycemic events in the Lucidity trial.